share_log

Pfizer's cancer drug partner mulls sale

Pfizer's cancer drug partner mulls sale

輝瑞的抗癌藥物合作伙伴考慮出售
Benzinga Real-time News ·  2022/07/16 00:23

  • Bloomberg reports that $Pfizer(PFE.US)$ cancer drug partner $CSTONE PHARMACEUTICALS(CSPHF.US)$ in China is considering strategic options, including a sale.

  • The report added that the Chinese firm backed by WuXi AppTec Co is working with $Goldman Sachs(GS.US)$ to help pan out potential bidders.

  • WuXi AppTec is the largest shareholder in CStone with a 24.7% stake, according to the data compiled by Bloomberg. Pfizer has around a 10% stake in the company.

  • In June, the Pfizer-CStone partnered Cejemly (sugemalimab) got an expanded approval in China for unresectable stage 3 non-small cell lung cancer (NSCLC) that hasn't progressed following chemoradiotherapy. 

  • The drug was initially approved in December for use alongside chemotherapy in newly diagnosed metastatic NSCLC.

  • Pfizer had signed on to help develop and lead the marketing of Cejemly in China in 2020. The deal saw the pharma giant make a $200 million equity investment 

  • Bloomberg noted that CStone shares were suspended two months ago after an investigation into an investment suggested breached listing rules.

  • 彭博社報道稱 $輝瑞(PFE.US)$抗癌藥物合作伙伴$CSTONE製藥公司(CSPHF.US)$正在考慮戰略選擇，包括出售。

  • 報道補充説，由藥明康德公司支持的中國公司正在與$高盛(GS.US)$幫助找出潛在的競標者。

  • 根據彭博社彙編的數據，藥明康德是中通的最大股東，持有24.7%的股份。輝瑞持有該公司約10%的股份。

  • 今年6月，輝瑞和Cstone合作的Cejemly(Sugyalimab)在中國獲得了擴大批准，用於治療不能切除的3期非小細胞肺癌(NSCLC)，這種癌症在放化療後沒有進展。

  • 該藥物最初於去年12月被批准與化療一起用於新診斷的轉移性非小細胞肺癌。

  • 2020年，輝瑞簽約幫助開發和領導Cejemly在中國的營銷。在這筆交易中，這家制藥巨頭進行了2億美元的股權投資

  • 彭博社指出，兩個月前，在對一項投資的調查顯示，CStone違反了上市規則後，CStone的股票被停牌。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論